ClinicalTrials.gg
RecruitingNCT07505394PREVENT-ICDUpdated Oct 16, 2026

Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease

An interventional study of Algorithm-guided group and Standard of Care (SoC) group in Parkinson Disease and Impulse Control Disorder, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingFirst site in France+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
528
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Parkinson Disease by Assistance Publique - Hôpitaux de Paris — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
Largest of 15
528 · median 60
Started
2026
with 1 other
No phase
10 of 21
3 open now
Registered
21st of 21
by date

Among the 21 studies in Parkinson Disease by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 21st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 21 studies in Parkinson Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Parkinson Disease by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Impulse control disorders and related behaviors (ICDRBs) are characterized by pathological gambling, compulsive shopping or eating, and hypersexuality, but other related behaviors have been described, e.g. hobbyism, and punding. ICDRBs are frequent in Parkinson's Disease (PD), affecting up to 50% of the patients after 5 years with major medical, social, and legal impact, with life changing consequences for patients and caregivers. The main risk factor is dopaminergic therapy, particularly the cumulative dose of dopamine agonists (DA). On the other hand, the dopaminergic therapy is necessary to control motor symptoms, and DA have demonstrated efficacy in delaying motor complications occurring in PD. Ideally, dopaminergic therapy would have to be adjusted to the individual risk of developing ICRDBs to maximize the benefit/risk ratio of each drug. However, despite several clinical risk factors associated with the risk of ICDRBs (in addition to the dopaminergic therapy), it is still not possible to predict their risk at the individual level, and not every patient treated with dopaminergic medications will develop ICDRBs. A machine learning algorithm to predict ICDRBs, based on clinical data, validated by cross-validation on independent replication cohorts has been developed. The PREVENT-ICD study proposes to test the efficacy of a new application, ICD-Shield, based on an algorithm to predict and prevent ICDs,in a multicenter randomized controlled trial to prevent ICDRBs in PD patients by proposing to the clinician treatment adjustment according to the risk predicted by the algorithm, as compared to the standard of care (SoC)

Read the detailed description

This Clinical Investigation is a multicenter comparative randomized, controlled, masked (patient and primary criteria evaluator), superiority trial, with 2 parallel groups (Intervention group: Algorithm-guided arm; Control group: standard of care arm).

PD patients, treated by DA at inclusion, will be randomized (1:1 ratio) either to the standard of care (SoC) arm, or to the Algorithm-guided arm. They will be recruited at PD expert centers of the NSPARK/FCRIN network. The primary objective is to assess the efficacy of the ICD SHIELD app, a software with a computer-based algorithm assisting clinicians in the prescription of dopaminergic medications, as compared to the standard of care, on the primary endpoint After the inclusion (V0 at M0), four follow-up visits will be performed : V1 at M9, V2 at M18, V3 at M27 and V4 at M36 during outpatients clinics where participants are usually followed. At each follow up visit (M9 to M36), the neurologist will record medical and treatment history, perform neurological examination MDS-UPDRS sections III to IV and CGI-I scale, and will review the MDS-UPDRS sections I and II for potential reassessment/clarification. The PGI scale, PDQ39 questionnaire, MDS-UPDRS sections I and II, and the HAD scales will be filled by the patient. The MoCA scale, ASBPD and QUIP-RS will be performed by a neuropsychologist, or an investigator trained for each scale, according to scoring instructions and blind to treatment arm allocation. Then, the treatment will be adapted by the neurologist, according to the recommendation by the algorithm output or to the clinician sole recommendation depending on the arm in which the patient is randomized.

An additional phone call will be made 3 months after the previous visit for a remote checkup to confirm that the prescription change (decreasing or stopping DA) has been properly followed by the patient, if the adjustment to stop completely or decrease DA to a dose equivalent of 40mg of Levodopa was applied.

An optional blood sample will be drawn at baseline or at a follow-up visit and sent for DNA extraction and biobanking at the ICM, Pitié-Salpêtrière Hospital, Paris. The duration of recruitment will be 2 years. The duration of participation for each participant will be 3 years, the total duration of the study will be 5 years.

The main analysis will be in Intention to treat and will involve a mixed generalized linear model (GLMM) with a logit link adjusted for minimization stratification factors (center, sex, age, Levodopa Equivalent Daily Dose (LEDD) at inclusion).

03

Conditions studied

  • Parkinson Disease
  • Impulse Control Disorder

Keywords

  • Agonists, Dopamine
  • Impulse Control Disorders
  • ICD SHIELD app
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female ≥ 18 years old
  • Diagnosis of PD according to the 2015 Movement Disorders Society criteria (Postuma et al., Mov Disord. 2015), with bradykinesia AND at least ONE of the following: muscular rigidity, or resting tremor; with no other suspected cause of parkinsonism
  • Disease duration below 6 years included
  • No ongoing (Mild or above) ICDRBs (any ASBPD part IV subscores in any of the items 3 to 5 and 7 to 10 each \<2)
  • Patients currently treated with DA for at least 2 months and without current planned or known reason for stopping DA over the next 3 years

Exclusion criteria

Exclusion Criteria:

  • Atypical or secondary parkinsonism such as supranuclear palsy, multisystem atrophy or drug-induced parkinsonism, etc...

    • Patients with a cognitive or psychiatric disorder preventing patient's participation as per investigator's judgement
    • Not willing to participate to the Clinical Investigation or to sign the consent
    • Pregnant or lactating woman, or tested positive in \<serum or urine> pregnancy test
    • Participation in drug trials within 30 days prior to screening or within 5 half-life of investigational product whatever the longest
    • Participant not affiliated or beneficiary of a French social security system
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
528 participants (estimated)

Study arms

  • Experimental
    Algorithm-guided group

    In the (algorithm-guided arm) the patient treatment will be adapted by the neurologist based on the algorithm output.

    Device: Algorithm-guided group

  • Other
    Standard of Care (SoC) group

    In the SoC arm the patient treatment will be adapted by the neurologist based only on their clinical appreciation and international guidelines.

    Behavioral: Standard of Care (SoC) group

Interventions

  • DeviceAlgorithm-guided group

    After the evaluation of the patient and the clinical inputs entered in the ICD SHIELD app including the planned choice of prescription by the neurologist for the next period, the clinician will receive the therapeutic approach recommended by the ICD SHIELD app depending on the output given by the algorithm. The clinician can repeat the use of the app if he/she plans to try various choice of prescription in the app if deemed necessary, but a single use is recommended at each visit. The neurologist will have to follow the recommendation of the ICD SHIELD app as much as possible unless judged inappropriate. The neurologist makes the final decision.

  • BehavioralStandard of Care (SoC) group

    In the SoC arm the patient treatment will be adapted by the neurologistbased only on their clinical appreciation and international guidelines.

06

What researchers measure

Primary outcomes

  1. Rate of patients with at least one clinically significant ICDRBs, i.e mild or above (any ASBPD score at 2 or above in any of the subcategories 3 to 5 and 7 to 10 of part IV) over the 3 year-follow up.

    ICDRBs will be screened for, every 6 months, with the internationally validated Ardouin Scale of Behavior in PD (ASBPD), according to scoring instructions, by a neuropsychologist or the neurologist trained for the scale. The diagnosis of a clinically significant ICDRB (MILD or above) relies on part IV of the ASBPD, hyperdopaminergic behaviors, for patients who score at 2 or above in any of the subcategories 3 to 5 and 7 to 10

    Time frame: over 3 years

Secondary outcomes

  1. Perception of global disease severity by the patient

    Change in disease severity of PD on the Patient Global Impression of Improvement (PGI-I) scale filled by the patient over the 3 year-long-follow up. The PGI is a Patient Global Impression 7-point scale that requires the rating of the severity of the patient's illness at the time of assessment. It is assessed by asking the patient at each visit which alternative described how they had felt during the last 7 days as compared to how they felt at the baseline observation. A higher value indicates increased improvement from Clinical Investigation start, ranging from 1=very much worse to 7=very much improved.

    Time frame: over 3 years

  2. Perception of global disease severity by the clinician

    Change in disease severity of PD on the Clinical Global Impression of Improvement (CGI-I) scale filled by the clinician over the 3 year-long-follow up. The Change in the Neurologist (clinician) Global Impression of Improvement (CGI-I) provides a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. The Clinical Global Impression-Improvement scale rates total improvement on a 7-point scale: 1= Very much improved; 2= Much improved; 3= Minimally improved; 4= No change; 5= Minimally worse; 6= Much worse; 7= Very much worse.

    Time frame: over 3 years

  3. Time to onset of first occurrence of clinically significant ICDRBs

    Time to onset of a first clinically significant ICDRBs, i.e mild or above, defined as any ASBPD score at 2 or above in any of the subcategories 3 to 5 and 7 to 10 of part IV over the 3 year-long-follow up.

    Time frame: over 3 years

  4. Global severity of ICDRBs at time of first occurrence on the QUIP-RS score

    Severity of ICDRBs at time of first occurrence assessed on the Questionnaire For Impulsive-Compulsive Disorders In Parkinson's Disease-Rating Scale (QUIP-RS) score (Score ranges from 0 to 112, a higher score reflecting a more severe ICDRB) over the 3 year-long-follow up.

    Time frame: over 3 years

  5. Highest severity of ICDRBs at time of first occurrence on the ASBPD score

    Severity of ICDRBs at time of first occurrence assessed on ASBPD score (highest severity on part IV of the ASBPD, hyperdopaminergic behaviors, in any of the subcategories 3 to 5 and 7 to 10) over the 3 year-long-follow up.

    Time frame: over 3 years

  6. Global severity of ICDRBs at time of first occurrence on the ASBPD score

    Global severity of ICDRBs at time of first occurrence assessed by the sum of ICDRBs items' scores on ASBPD (subcategories 3 to 5 and 7 to 10 of the part IV hyperdopaminergic behaviors) over the 3 year-long-follow up.

    Time frame: over 3 years

  7. Cumulative levodopa equivalent daily dose (LEDD)

    Intakes of dopaminergic medications will be calculated to an equivalent dose of levodopa allowing for standardized evaluation of medication intake among PD patients by expressing dose intensity of different antiparkinsonian drug regimens on a single scale ((Jost et al., 2023; Tomlinson et al., 2010). Cumulative LEDD will be assessed as the sum of the daily doses over the 3 year-follow up, recorded at each visit (M9 M18, M27, M36).

    Time frame: over 3 years

  8. Time to first DA stopping

    Time to onset of a first DA stopping, whatever the reason, over the 3 year-long-follow up.

    Time frame: over 3 years

  9. Reasons for first DA stopping

    Rate of each reasons given by the neurologist for the first DA stopping over the 3 year-long-follow up, among: clinically significant ICDRBs, other adverse event of DA than ICDRBs, risk of clinically significant ICDRBs as judged by the neurologist and/or the ICD SHIELD app, insufficient efficacy, other or unknown reason.

    Time frame: over 3 years

  10. Motor control

    Change in motor score on the MDS-UPDRS (MDS-UPDRS III sub-score) over the 3 year-long-follow up. Score between 0 and 132, a higher score reflects a more severe motor state. The MDS-UPDRS III sub-score is the gold standard for measuring the clinical motor state of PD patients.

    Time frame: over 3 years

  11. Dyskinesia

    Change in the dyskinesia score on the MDS-UPDRS (sum of MDS-UPDRS IV items 4.1 and 4.2) over the 3 years.

    Time frame: over 3 years

  12. Motor fluctuation

    Change in the motor fluctuations score on the MDS-UPDRS (sum of MDS-UPDRS IV items 4.3 to 4.6) over the 3 years.

    Time frame: over the 3 years.

  13. Depression (MDS-UPDRS scale)

    Change in depression score item 1.3 of the MDS-UPDRS scale over the 3 year-follow up

    Time frame: over 3 years

  14. Depression (HADS subscore)

    Change in HADS depression subscore over the 3 year-follow up. It comprises 14 items each ranging from 0 to 3. Seven questions are evaluating anxiety (total A) and seven others to depressive dimension (total D), obtaining two scores (maximal score = 21 for each). A higher value indicates increased anxiety (total A) or depression (total D).

    Time frame: over 3 years

  15. Anxiety (MDS-UPDRS scale)

    Change in anxiety score item 1.4 of the MDS-UPDRS scale over the 3 year-follow up

    Time frame: over 3 years

  16. Anxiety (HADS subscore)

    Change in HADS anxiety subscore over the 3 year-follow up. It comprises 14 items each ranging from 0 to 3. Seven questions are evaluating anxiety (total A) and seven others to depressive dimension (total D), obtaining two scores (maximal score = 21 for each). A higher value indicates increased anxiety (total A) or depression (total D).

    Time frame: over 3 years

  17. Somnolence

    Change in somnolence score item 1.8 of the MDS-UPDRS over the 3 year-follow up

    Time frame: over 3 years

  18. Sleep disorders

    Change in sleep issues score item 1.7 of the MDS-UPDRS over the 3 year-follow up

    Time frame: over 3 years

  19. Apathy

    Change in apathy score item 1.5 of the MDS-UPDRS scale over the 3 year-follow up

    Time frame: over 3 years

  20. Cognition

    Change in cognition MoCA scale over the 3 year-follow up. The MoCA is a 30-point cognitive screening instrument that assesses visuospatial, executive, naming, attention, language, abstraction, delayed recall, and orientation domains. A cutoff score of 26 is normative cognitive function.

    Time frame: over 3 years

  21. Serious Adverse Events

    Number, type and imputability of serious adverse events within a 3 year follow up period.

    Time frame: over 3 years

  22. Observance of the ICD SHIELD app for clinicians

    Percentage of visits in which the clinician decided not to follow ICD SHIELD app recommendation over the 3 year-follow up

    Time frame: over 3 years

  23. Acceptability of the ICD SHIELD app for clinicians

    Reasons for not following the ICD SHIELD app recommendation: a short open-ended questionnaire to assess the acceptability of the intervention. These open-ended questions will be analyzed qualitatively

    Time frame: over 3 years

Other outcomes

  1. Cumulative severity of ICDRBs

    Cumulative severity of ICDRBs within the 3-year period assessed by the sum of the QUIP-RS score at each visit (M9, M18, M27, M36)

    Time frame: over 3 years

  2. Subtypes of ICDRBs

    Change in each subtype of ICDRBs within the 3-year period assessed by each respective QUIP-RS sub-score (sub-scores A to G). Score ranges from 0 to 16 for each category. A higher score reflects a more severe ICD.

    Time frame: over 3 years

  3. Patient quality of life

    Change in the quality of life measured by PDQ-39 scale score over the 3 year-follow up. A higher score reflects a poorer quality of life.

    Time frame: over 3 years

  4. Body weight change

    Change in body weight (in kg, measured at each patient visit) over the 3 year-long-follow up

    Time frame: over 3 years

  5. Cumulative dose of DA

    Cumulative DA doses assessed by the sum of the daily doses over the 3 year-follow up

    Time frame: over 3 years

  6. Cumulative dose of levodopa

    Cumulative levodopa doses assessed by the sum of the daily doses over the 3 year-follow up

    Time frame: over 3 years

  7. Cumulative dose of COMT inhibitors

    Cumulative COMT inhibitors doses assessed by the sum of the daily doses over the 3 year-follow up

    Time frame: over 3 years

  8. Cumulative dose of MAO-B inhibitors

    Cumulative MAO-B inhibitors doses assessed by the sum of the daily doses over the 3 year-follow up,

    Time frame: over 3 years

  9. Cumulative dose of anticholinergic treatments

    Cumulative anticholinergic doses assessed by the sum of the daily doses over the 3 year-follow up,

    Time frame: over 3 years

  10. Cumulative dose of amantadine treatments

    Cumulative amantadine doses assessed by the sum of the daily doses over the 3 year-follow up.

    Time frame: over 3 years

  11. Monthly LEDD

    Change in monthly LEDD over the 3 years. Monthly LEDD calculated as the mean of the LEDD over each month.

    Time frame: over 3 years

  12. Adverse events causing DA stopping or decrease

    Rate of patient with a DA stopping or decrease for any other adverse events reason than ICD (lower limbs swelling, Excessive Daytime Sleepiness, fainting or dizziness due to orthostatic hypotension, hallucinations, …), as judged by the neurologist, over the 3 year-follow up

    Time frame: over 3 years

  13. Occurrence of Dopamine Agonist Withdrawal Syndrome (DAWS)

    Rate of patients with a DAWS over the 3 year-follow up. DAWS is defined as the occurrence or significant worsening of one or more nonmotor symptoms such as anxiety, panic attacks, depression, agitation, irritability, drug craving, insomnia, daytime fatigue, diaphoresis, nausea, vomiting, flushing, orthostasis, and generalized pain in the context of discontinuation or tapering of DA (Debove et al. 2024), as judged by the neurologist.

    Time frame: over 3 years

  14. Additional unscheduled visits due to adverse events

    Number of additional unscheduled visits due to adverse events to the neurologist over the 3 year-follow up.

    Time frame: over 3 years

  15. Genetic standardized net benefit statistic

    13 candidate variants selected from the DRD2, DRD3, DAT1, COMT, DDC, GRIN2B, ADRA2C, SERT, TPH2, HTR2A, OPRK1 and OPRM1 genes. In the standard of care arm, change in the standardized net benefit statistic, change in true positive rates, change in false positive rates, between the algorithm with and without genomic results, calculated at threshold that would be considered the most relevant for each algorithm

    Time frame: over 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request to the Coordinating Principal Investigator/Corresponding author, and according to local regulations and depending on futur use of the medical device in case of CE mark and commercialization. The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodological sound proposal, with clearly identified processing purposes and subject to compliance with applicable regulations (CNIL, GDPR)

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2031, 60 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 60 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Jul 2026 → Oct 2026, primary completion Jun 2031 → Oct 2031 and completion Jun 2031 → Oct 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Apr 1, 2026
StartActual
Oct 13, 2026was Jul 2026
Primary completionEst.
Oct 15, 2031was Jun 2031
CompletionEst.
Oct 15, 2031was Jun 2031
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
1 site added — first site in France
Show site
  • CHU Pitié Salpêtrière, APHP service de neurologie · Paris, France
Oct 16, 2026
Start date
Jul 1, 2026→Oct 13, 2026 (actual)
Oct 16, 2026
Primary completion
Jun 1, 2031→Oct 15, 2031
Oct 16, 2026
Study completion
Jun 1, 2031→Oct 15, 2031
Oct 16, 2026
Contact
Study contact's phone or email changed: •••2748→•••2748; •••7575→•••7575. See the current contact
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in France
    Show site
    • CHU Pitié Salpêtrière, APHP service de neurologie · Paris, France
    Start date Jul 1, 2026→Oct 13, 2026 (now actual)
    Primary completion Jun 1, 2031→Oct 15, 2031
    Study completion Jun 1, 2031→Oct 15, 2031
    Contact Study contact's phone or email changed: •••2748→•••2748; •••7575→•••7575. See the current contact
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07505394
Collaborators
NS-PARK Network
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Oct 13, 2026
Primary completion
Oct 15, 2031 (estimated)
Completion
Oct 15, 2031 (estimated)
Last update
Oct 16, 2026

Study contacts

Louise-Laure Mariani, Doctor
Contact
louise-laure.mariani@aphp.fr
(+33) 1 42 16 27 48
Sofia Zemouri, Master
Contact
sofia.zemouri@aphp.fr
(+33) 1 42 16 75 75
Louise-Laure Mariani
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion